Frommhold H, Guttenberger R, Henke M
Strahlentherapie, Radiologische Universitätsklinik Freiburg/Br.
Strahlenther Onkol. 1998 Dec;174 Suppl 4:31-4.
Numerous publications have reported an impaired radiocurability when anemia is present. Tissue hypoxia and consecutive radioresistance are speculated to be the underlying causes.
Our own retrospective data impressively confirm these observations: in an analysis of 889 patients homogeneously irradiated for head and neck cancer for locoregional tumor control and survival, anemia has proven to be a highly significant risk factor. Furthermore, hemoglobin content is an independent and, at least equally powerful predictor for outcome when compared to the known risk factors of site, treatment modality, resection status, T-, and N-stage.
In an attempt to improve therapeutic outcome, 50 anemic patients undergoing radiotherapy were treated with erythropoietin (rhEPO). A weekly increment in hemoglobin content of 0.7 g/dl was documented without any major side effects. Additionally, it seems that patients reacting sufficiently to rhEPO stimulation can expect better locoregional tumor control within the irradiation volume. This, however, awaits confirmation in an ongoing trial.
众多出版物报道，存在贫血时放射可治愈性受损。组织缺氧及随之而来的放射抗性被推测为潜在原因。
我们自己的回顾性数据有力地证实了这些观察结果：在一项针对889例因局部区域肿瘤控制和生存而接受头颈部癌均匀照射的患者的分析中，贫血已被证明是一个高度显著的风险因素。此外，与已知的部位、治疗方式、切除状态、T分期和N分期等风险因素相比，血红蛋白含量是一个独立的、且至少同样有力的预后预测指标。
为了改善治疗效果，对50例接受放疗的贫血患者使用促红细胞生成素（rhEPO）进行治疗。记录到血红蛋白含量每周增加0.7 g/dl，且无任何严重副作用。此外，似乎对rhEPO刺激反应充分的患者有望在照射区域内实现更好的局部区域肿瘤控制。然而，这一点有待正在进行的试验予以证实。
